Insider trade

Director sold ~$24K of ROIV shares in the open market

Traded Sep 15, 2026 · Filed Sep 18, 2026

Why it stands out

A Roivant Sciences director sold $24K of Roivant Sciences shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Director<$25KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$24,228

Shares × reported transaction price

Timing vs results

40 days after results of Aug 6, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−10.0%	+1.3%	−11.3%

Past results only. Not a forecast.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.25 to $40.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026.

Filed yesterday

Traded Oct 1 · filed 5 days later

Derivative exercise or conversion — not an open-market buy.

Scheduled in advanceFiled yesterday

Scheduled in advanceFiled yesterday